A5039377987- Inflammatory Bowel Disease
- Microscopic Colitis
- Eosinophilic Esophagitis
- Diagnosis and treatment of tuberculosis
- Autoimmune and Inflammatory Disorders
- Liver Diseases and Immunity
- Immunodeficiency and Autoimmune Disorders
- Healthcare Regulation
- Health Systems, Economic Evaluations, Quality of Life
- Healthcare during COVID-19 Pandemic
- Children's Physical and Motor Development
- Medical Device Sterilization and Disinfection
- Arts and Performance Studies
- Appendicitis Diagnosis and Management
- Dermatologic Treatments and Research
- Acute Lymphoblastic Leukemia research
- Diagnosis and Treatment of Venous Diseases
- Gastric Cancer Management and Outcomes
- Pregnancy and Medication Impact
- Public Health in Brazil
- Geography and Environmental Studies
- Stoma care and complications
- Brazilian cultural history and politics
- Cultural, Media, and Literary Studies
- Intestinal and Peritoneal Adhesions
D’Or Institute for Research and Education
2018-2024
Pfizer (United Kingdom)
2023
Janssen (Switzerland)
2023
Universidade Estadual Paulista (Unesp)
2023
Universidade Federal de Juiz de Fora
2023
AbbVie (United States)
2023
Takeda (France)
2023
Hospital de Clínicas
2018-2023
Pfizer (United States)
2023
Janssen (Belgium)
2023
Abstract Background Real-world data on the effectiveness and safety of ustekinumab (UST) in ulcerative colitis (UC) are lacking Latin America. In this study, we aimed to describe UST a real-world multicenter cohort Brazilian patients with UC. Methods We conducted retrospective observational including moderate-to-severe UC (total Mayo score 6–12, an endoscopic subscore 2 or 3) who received UST. The co-primary endpoints were clinical remission, defined as total ≤2 at 1 year, combined rectal...
ABSTRACT BACKGROUND: Inflammatory bowel diseases (IBD) are chronic inflammatory affections of recurrent nature whose incidence and prevalence rates have increased, including in Brazil. In long term, they responsible for structural damage that impacts quality life, morbidity mortality patients. OBJECTIVE: To describe the profile physicians who treat IBD patients as well characteristics care, unmet demands difficulties. METHODS: A questionnaire containing 17 items was prepared sent to 286 from...
ABSTRACT BACKGROUND: Adalimumab is a monoclonal antibody, tumor necrosis factor-alpha (TNFα) inhibitor that has efficacy for inducing and maintaining remission in moderate-to-severe ulcerative colitis. Real world studies with adalimumab Latin American colitis patients are scarce. OBJECTIVE: To assess the clinical rates induction maintenance therapy METHODS: Observational, multicenter retrospective study on case series of under therapy. The variables analyzed were: demographic data, previous...
ABSTRACT BACKGROUND: There is scarce data regarding efficacy and safety of vedolizumab in inflammatory bowel diseases Latin America. OBJECTIVE: To describe the first observational real-world experience with American patients. METHODS: Retrospective multicentric study patients Crohn’s disease (CD) ulcerative colitis (UC) who used at any phase their treatment. Clinical remission response (according to Harvey-Bradshaw index for CD Mayo score UC), mucosal healing, need surgery adverse events...
This prospective, observational, open-label study aimed to provide access ustekinumab prior market authorization and assess its safety effectiveness in patients with Crohn's disease (CD) refractory anti-tumor necrosis factor-α conventional drugs Brazil. Patients a diagnosis of moderate-to-severe active CD for ≥3 months before screening received single intravenous induction dose (~6 mg/kg) at week 0, 90 mg maintenance dose, subcutaneously, every 8 or 12 weeks, from through 80. Serious adverse...
INTRODUÇÃO: há uma preocupação crescente com os custos da terapia biológica no tratamento DC. O objetivo deste estudo foi simular o custo-minimização do contínuo IFX e ADA em portadores de DC, num período 1 ano, variadas faixas peso. MÉTODO: farmacoeconômico na simulação agentes biológicos pacientes pesos diferentes. Os foram baseados preço dos dois medicamentos isoladamente (IFX E ADA). RESULTADOS: custo (sistema público) R$ 29.411,12 (entre 20 40 kg), 44.116,68 41 60 58.822,24 61 80 kg)...
Consistently defining disease activity remains a critical challenge in the follow-up of patients with Crohn's (CD). We investigated potential applicability abdominal ultrasonography color Doppler (USCD) analysis for detection morphological alterations and inflammatory CD.Forty-three CD ileitis/ileocolitis were evaluated using USCD measurements obtained on terminal ileum right colon. Sonographic parameters included wall thickening, stricture, hyperemia, presence intra-abdominal mass,...
Abstract Background Anti-TNF therapy represented a landmark in medical treatment of ulcerative colitis (UC). There is lack data on the efficacy and safety these agents Brazilian patients. The present study aimed to analyze rates clinical endoscopic remission comparatively, between adalimumab (ADA) infliximab (IFX), patients with UC, evaluate factors associated after 1 year treatment. Methods A national retrospective multicenter (24 centers) was performed including UC treated anti-TNF...
A acao dos musculos extensores da coluna tem sido estudada atraves eletromiografia visando conhecer a participacao muscular durante varias posturas corporais. Neste trabalho, o objetivo foi verificar participacao do musculo iliocostal lombar (eretor espinha), os movimentos de flexao e extensao tronco na posicao sentada. Na sentada foram realizados em cadeira sem encosto no solo. Participaram estudo 12 individuos sexo masculino, sedentarios, faixa etaria 36 52 anos, com idade media 46,16...
The IBD National Patient Registry is an initiative of the GEDIIB (Brazilian Study Group Inflammatory Bowel Disease) who aims to survey epidemiological profile patients through creation a centralized registry with data on monitored in public and private health services which will allow planning actions by facilitate diagnosis access treatment IBD, enabling implementation partnership government agencies improve care and, consequently, quality life IBD. This study show results Registry.A cohort...